通化金马：化学1类新药琥珀八氢氨吖啶片已完成各项专业审评工作进入综合审评环节，审评处于正常进行中

Core Viewpoint - The company has developed a new chemical drug, Amber Tetrahydroaminoacridine Tablets, aimed at treating mild to moderate Alzheimer's disease, and it is currently in the comprehensive review stage after completing all professional evaluation work [1]. Group 1 - The new drug is classified as a Class 1 chemical new drug [1]. - The company assures that it will disclose any information that meets the disclosure standards as per relevant regulations [1]. - The review process for the new drug is progressing normally [1].